Adaptive Biotechnologies Corp Stock Today
| ADPT Stock | USD 10.45 0.00 0.00% |
PerformanceGood
| Odds Of DistressLow
|
Adaptive Biotechnologies is selling for under 10.45 as of the 21st of July 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 10.25. Adaptive Biotechnologies has less than a 13 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 22nd of April 2025 and ending today, the 21st of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of June 2019 | Category Healthcare | Classification Health Care |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. The company has 151.92 M outstanding shares of which 10.13 M shares are presently shorted by private and institutional investors with about 7.32 trading days to cover. More on Adaptive Biotechnologies Corp
Moving together with Adaptive Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Adaptive Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO CoFounder | Chad MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAdaptive Biotechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adaptive Biotechnologies' financial leverage. It provides some insight into what part of Adaptive Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adaptive Biotechnologies Corp (ADPT) is traded on NASDAQ Exchange in USA. It is located in 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 and employs 619 people. Adaptive Biotechnologies is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.58 B. Adaptive Biotechnologies conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 151.92 M outstanding shares of which 10.13 M shares are presently shorted by private and institutional investors with about 7.32 trading days to cover.
Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Check Adaptive Biotechnologies Probability Of Bankruptcy
Ownership AllocationAdaptive Biotechnologies holds a total of 151.92 Million outstanding shares. The majority of Adaptive Biotechnologies Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adaptive Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adaptive Biotechnologies. Please pay attention to any change in the institutional holdings of Adaptive Biotechnologies Corp as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million fourty-eight thousand two hundred twenty-seven invesors are currently shorting Adaptive Biotechnologies expressing very little confidence in its future performance.
Check Adaptive Ownership Details
Adaptive Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aristotle Atlantic Partners, Llc | 2025-03-31 | 2.9 M | |
| Geode Capital Management, Llc | 2025-03-31 | 2.8 M | |
| State Street Corp | 2025-03-31 | 2.7 M | |
| Massachusetts Financial Services Company | 2025-03-31 | 2.3 M | |
| Driehaus Capital Management Llc | 2025-03-31 | 2.2 M | |
| Blue Water Life Science Advisors, Llc | 2025-03-31 | 2.1 M | |
| Iron Triangle Partners Lp | 2025-03-31 | 2.1 M | |
| Goldman Sachs Group Inc | 2025-03-31 | 2 M | |
| Victory Capital Management Inc. | 2025-03-31 | 1.8 M | |
| Viking Global Investors Lp | 2025-03-31 | 30 M | |
| Rubric Capital Management Lp | 2025-03-31 | 13.1 M |
Adaptive Biotechnologies Historical Income Statement
Adaptive Stock Against Markets
Adaptive Biotechnologies Corporate Management
| Stacy JD | General VP | Profile | |
| Stacy Taylor | General VP | Profile | |
| Yi Zhou | Chief Officer | Profile | |
| Tycho Peterson | Chief Officer | Profile | |
| Kyle Piskel | Principal Officer | Profile | |
| Susan Bobulsky | Chief MRD | Profile |
Already Invested in Adaptive Biotechnologies Corp?
The danger of trading Adaptive Biotechnologies Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptive Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptive Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptive Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.